"Avamed Synergy obtains, from the Valencian Institute of Competitiveness and Innovation (IVACE+i), the approval and financing of the BOHEMIA3 project, in which several agents of the Valencian Innovation System (SVI) cooperate".

The project aims to research, develop technology and validate new tools to predict and minimise the incidence of arterial wall rupture in Abdominal Aortic Aneurysm.

Among other actions, IVACE-i supports high-impact collaborative initiatives to address challenges of common interest and promotes, among other actions, projects that enhance the consolidation of the whole business value chain. It also promotes the intensification of the use of knowledge by companies and innovative public procurement as an instrument for the development of technologies and innovations aimed at improving the quality and efficiency of public services.

Within the framework of its programme "Consolidation of the Business Value Chain", the aim of the project is to support the development of R&D&I projects that involve the application of innovation in products or processes or in the organisational systems of the applicants.

In this way, the initiatives are able to influence or have an effect on other companies in the value chain by incorporating innovation in their products, improving their organisational systems or increasing their economic activity in general. Likewise, IVACE-i aims to support projects such as BOHEMIA3 that promote the development and use of other key technologies to boost industrial and economic development.

The innovation project led by Avamed Synergy, "Innovative biomechanical, haemodynamic and morphometric analysis of aortic aneurysms" (BOHEMIA3), has been approved by the Valencian Institute of Competitiveness and Innovation (AVI) (IVACE+ i Innovation) and co-financed by the ERDF Operational Programme of the Valencian Community 2021-2027. It thus contributes to the political objective (OP1): "A more competitive regional Europe through information and communication technologies", and particularly to the specific objective "the development and improvement of research and innovation capacities and the implementation of advanced technologies".

BOHEMIA3 strengthens the research and development of new Artificial Intelligence tools for medical image segmentation, prediction and visualisation in a 3D environment of vascular and arterial anatomical structures affected by complex pathologies such as AAA (Abdominal Aortic Aneurysm). Thanks to this, greater precision will be achieved in clinical analysis, autonomously and by means of alert systems.

Once the clinical need has been identified, BOHEMIA3 provides a novel methodology in an intelligent environment assisted by Artificial Intelligence, where the doctor can quantify with greater precision the possible risk of AAA rupture.

The project will generate knowledge in human biology and medical image processing, useful for research centres and universities, and will enable biotech companies to develop new biomarkers and innovative solutions. It will also impact companies in surgical software, 3D printing and extended reality, fostering collaboration and growth in these industries.

Finally, it will improve the healthcare system through the personalisation of treatments and reduce costs associated with incorrect diagnoses, benefiting both the Regional Ministry of Health of the Generalitat Valenciana and the National Health System. Avamed Synergy continues, in this way, to face clinical challenges that improve people's quality of life and facilitate the work of healthcare personnel.